Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1211567#aggregation> ?p ?o. }
Showing items 1 to 48 of
48
with 100 items per page.
- aggregation classification "A1".
- aggregation creator B583158.
- aggregation creator B583159.
- aggregation creator B583160.
- aggregation creator B583161.
- aggregation creator B583162.
- aggregation creator B583163.
- aggregation creator B583164.
- aggregation creator B583165.
- aggregation creator B583166.
- aggregation creator B583167.
- aggregation creator B583168.
- aggregation creator B583169.
- aggregation creator B583170.
- aggregation creator B583171.
- aggregation creator B583172.
- aggregation creator B583173.
- aggregation creator person.
- aggregation date "2011".
- aggregation format "application/pdf".
- aggregation hasFormat 1211567.bibtex.
- aggregation hasFormat 1211567.csv.
- aggregation hasFormat 1211567.dc.
- aggregation hasFormat 1211567.didl.
- aggregation hasFormat 1211567.doc.
- aggregation hasFormat 1211567.json.
- aggregation hasFormat 1211567.mets.
- aggregation hasFormat 1211567.mods.
- aggregation hasFormat 1211567.rdf.
- aggregation hasFormat 1211567.ris.
- aggregation hasFormat 1211567.txt.
- aggregation hasFormat 1211567.xls.
- aggregation hasFormat 1211567.yaml.
- aggregation isPartOf urn:issn:0028-4793.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Boceprevir for untreated chronic HCV genotype 1 infection".
- aggregation abstract "BACKGROUND : Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. METHODS : We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups. In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period). Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks. Nonblack patients and black patients were enrolled and analyzed separately. RESULTS : A total of 938 nonblack and 159 black patients were treated. In the nonblack cohort, a sustained virologic response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P<0.001), and in 213 of the 311 patients (68%) in group 3 (P<0.001). In the black cohort, a sustained virologic response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P = 0.04), and in 29 of the 55 patients (53%) in group 3 (P = 0.004). In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 weeks. Anemia led to dose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, respectively. CONCLUSIONS : The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 weeks of boceprevir.".
- aggregation authorList BK935450.
- aggregation endPage "1206".
- aggregation issue "13".
- aggregation startPage "1195".
- aggregation volume "364".
- aggregation aggregates 1212341.
- aggregation aggregates 4101610.
- aggregation isDescribedBy 1211567.
- aggregation similarTo LU-1211567.